Table 3:

Patients with late treatment-related toxicities

	NHT plus WPRT group (n=316)			NHT plus PORT group (n=313)			WPRT plus AHT group (n=317)			PORT plus AHT group (n=315)
	Grade 1–2	Grade 3	Grade 4	Grade 1–2	Grade 3	Grade 4	Grade 1–2	Grade 3	Grade 4	Grade 1–2	Grade 3	Grade 4
Bladder	185 (59%)	17 (5%)	1 (<1%)	183 (58%)	17 (5%)	0	199 (63%)	21 (7%)	1 (<1%)	178 (57%)	12 (4%)	2 (1%)
Bowel	199 (63%)	15 (5%)	4 (1%)	168 (54%)	4 (1%)	0	229 (72%)	9 (3%)	0	180 (57%)	5 (2%)	1 (<1%)
Haematological	90 (28%)	14 (4%)	7 (2%)	67 (21%)	9 (3%)	3 (1%)	80 (25%)	12 (4%)	7 (2%)	68 (22%)	7 (2%)	1 (<1%)
Liver	9 (3%)	2 (1%)	0	22 (7%)	2 (1%)	0	10 (3%)	1 (<1%)	0	15 (5%)	1 (<1%)	0
Not otherwise specified	56 (18%)	3 (1%)	0	52 (17%)	2 (1%)	0	71 (22%)	2 (1%)	0	59 (19%)	2 (1%)	0
Other gastrointestinal	60 (19%)	4 (1%)	1 (<1%)	33 (11%)	1 (<1%)	0	51 (16%)	1 (<1%)	0	48 (15%)	2 (1%)	0
Other genitourinary	60 (19%)	8 (3%)	0	52 (17%)	2 (1%)	0	73 (23%)	8 (3%)	0	55 (17%)	5 (2%)	0
Skin	90 (28%)	0	0	77 (25%)	2 (1%)	0	98 (31%)	1 (<1%)	0	87 (28%)	0	0

Data are n (%). There were no late grade 5 treatment-related events (deaths). NHT=neoadjuvant hormonal therapy. WPRT=whole pelvic radiotherapy. PORT=prostate only radiotherapy. AHT=adjuvant hormonal therapy. PSA=prostate-specific antigen.